Fresh Meadows, New York Clinical Trials

A listing of Fresh Meadows, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 414 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

platelet transfusions
recurrent melanoma
metastasis
bone marrow infiltration
neuroblastoma
Laura and Isaac Perlmutter Cancer Center at NYU Langone
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

measurable disease
nf2 gene
neurofibroma
schwartz
multiple meningiomas
Memorial Sloan Kettering Cancer Center (Site 210)
 (8.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

cemiplimab
endometrial cancer
stage iv non-small cell lung cancer
metastasis
metastatic melanoma
Icahn School of Medicine at Mount Sinai
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +8 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

metastatic malignant solid tumor
solid tumor
kras g12c mutation
kras
solid tumour
Memorial Sloan Kettering Cancer Center
 (8.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

opioid
analgesia
cancer
opioid use
high-dose chemotherapy
Memorial Sloan Kettering Cancer Center
 (8.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
The Young Heart Study

The purpose of our project is to better understand the characteristics of the young patients with coronary artery disease presenting for cardiac catheterization at our institution and to put forth a program to optimize their risk factors with a focus on gender differences. We will assess traditional and non-traditional risk …

arterial disease
cardiovascular disease
atherosclerosis
coronary disease
anxiety
Lenox Hill Hospital
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of AK104 a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

squamous cell carcinoma
bevacizumab
metastasis
formalin-fixed paraffin-embedded
adenosquamous carcinoma
Northwell Health LLC
 (5.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +19 other locations
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS.

myeloid leukemia
remission
hematologic malignancy
bone marrow procedure
cancer
Memorial Sloan Kettering Cancer Center
 (8.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +4 other locations
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see …

remission
minimal residual disease
bone marrow biopsy
leukemia
formalin-fixed paraffin-embedded
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
 (8.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
combination therapy
docetaxel
enzalutamide
cancer
New York University, Langone Health
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations